In the HY report, revenue in the UK segment increased from $36,432 to 195,178 from '12 to FY'13. Hard to say what is generating it, but a decent increase (on a small base) nonetheless.
I personally think with Jeremy Delk joining MLA as a board member during the current transitional, period we'll start seeing the similar level of marketing MLA to the masses as Medivet US currently does. (see their Twitter, facebook, news releases, and website activities).
Definitely a lull in newsflow, but overall I'm still positive about the long term potential of MLA. I still feel 30c is about right in the medium term, uintil further news is released.
DYOR etc
MLA Price at posting:
25.0¢ Sentiment: LT Buy Disclosure: Held
